Navigation Links
Perdue Kidd & Vickery Files Lawsuit Against Abbott Laboratories for Inadequate Leukemia and Cancer Warning
Date:7/29/2011

DALLAS, July 29, 2011 /PRNewswire/ -- Humira defect lawyers filed a lawsuit against Abbott Laboratories in Texas state court claiming Abbott's blockbuster drug, Humira, caused a life-threatening disease, leukemia.

"Eleven year-old Bo Anderson was prescribed Humira for a skin condition, psoriasis.  After taking the drug for approximately ten months, Bo's parents noticed unusual bruising covering his body while on a family vacation," says drug defect attorney Andy Vickery.

"Bo immediately underwent various tests and was diagnosed with T cell acute lymphoblastic leukemia; a dangerous side effect Abbott Laboratories knew could affect Humira users but failed to warn them about."  

Vickery says because of the Humira-induced leukemia, Bo now must continue to undergo intense treatment that could potentially cause long-term and serious side effects, and could possibly develop secondary cancers as he matures.

Prior to the launch of Humira in 2003, other similar drugs had been linked to lymphoma and other forms of cancer, and clinical trial data suggested that there was a very significant epidemiological "signal" about the risk.  Once Humira was launched, many adverse event reports were submitted regarding cancers, however Abbott did nothing to warn about this.  Bo was diagnosed with Leukemia on January 8, 2009, over seven months after the FDA said that physicians and patients should be warned about this side effect, and nearly ten months before a Black Box warning was finally issued regarding Humira-induced leukemia in pediatric and adolescent patients.

Humira (Adalimumab) is a class of biologic drugs known as TNF (Tumor Necrosis Factor) blockers. It works by blocking naturally occurring proteins that cause inflammation.  However, research has shown that taking drugs like Humira can compromise the immune system and can have a devastating and even deadly effect resulting in serious infections, cancer, allergic reactions, Hepatitis B virus reactivation, nervous system problems, heart failure, blood issues and certain immune reactions. Humira is used for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, crohn's disease, and plaque psoriasis. With 2010 sales of $6.5 billion, Humira is Abbott's flagship drug.

Perdue Kidd & Vickery is a national law firm of Board Certified Personal Injury Trial Lawyers.  The law practice is based in Houston, TX.   Further information is available at http://www.HumiraJustice.com. View an educational video about Humira fungal infections.


'/>"/>
SOURCE Perdue Kidd & Vickery
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
3. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
4. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
7. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
8. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
9. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
10. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
11. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2019)... ... March 20, 2019 , ... ... for outsourced research services and products, announced today that it has partnered ... services. The Canadian-based company offers RWE research, systematic literature review, comparative effectiveness ...
(Date:3/20/2019)... ... March 20, 2019 , ... On World Oral Health Day, ... MN, for his commitment and dedication to the oral health of patients in Africa. ... which aims to enhance the standards of care within African partner healthcare institutions. ...
(Date:3/19/2019)... ROYAL OAK, Mich. (PRWEB) , ... March 19, 2019 , ... ... Annual Baby Fair on Saturday, April 6 from 11am-2pm. The event is located ... W. 13 Mile Rd, Royal Oak, MI 48073. , Women’s Excellence offers giveaways, raffle ...
Breaking Medicine Technology:
(Date:3/20/2019)... Texas (PRWEB) , ... March 20, 2019 , ... ... Mobile Medical systems are being developed with Wi-Fi connectivity to allow portable devices ... pumps, heart and hypertension monitoring, glucose monitoring, and other wearable devices for home ...
(Date:3/20/2019)... CHAPEL HILL, N.C. (PRWEB) , ... March 20, ... ... in the sales and support of customized NextGen® Practice Management (PM) and Electronic ... Awards for Sales & Customer Service . This year marks the fifth consecutive ...
(Date:3/20/2019)... ... March 20, 2019 , ... ... pain from disc herniation's, degenerative disc disease, spinal stenosis, sciatica and numbness in ... location! , At Advanced Spine Joint and Wellness provider's work as a ...
(Date:3/20/2019)... (PRWEB) , ... March 20, 2019 , ... ... healthcare industry, announced today the launch of its mSource® Predictive Plan, a new ... most complete insights. It gives purchased services teams the control to develop a ...
(Date:3/20/2019)... ... 20, 2019 , ... AutismOne has announced that Dr. Andrew Wakefield, an author ... Dr. Wakefield's presentation at the AutismOne 2019 Conference will address what herd immunity is ... The lecture will examine the consequences - real and potential - for vaccines that ...
Breaking Medicine News(10 mins):